The tweet was deleted by the author.
But we saved everything 🙂.
CG Oncology, Inc. released its financial results for the first quarter ended March 31, 2026 and announced updates to its business operations.
The company, which focuses on urology and therapies for non-muscle invasive bladder cancer (NMIBC), provided further details on its performance and recent initiatives through the official report. Additional context and specific financial figures can be accessed through the company's published results.
CG Oncology has previously addressed the persistent risk of bladder cancer recurrence despite the availability of approved therapies for non-muscle invasive forms. In an earlier update, the company said it is exploring new treatment options for these patients. Additional information can be found in prior coverage of CG Oncology’s efforts targeting bladder cancer risk.